Folgen
Qingbin Cui
Qingbin Cui
Research Asistant Professor at The University of Toledo
Bestätigte E-Mail-Adresse bei utoledo.edu
Titel
Zitiert von
Zitiert von
Jahr
Modulating ROS to overcome multidrug resistance in cancer
Q Cui, JQ Wang, YG Assaraf, L Ren, P Gupta, L Wei, CR Ashby Jr, ...
Drug Resistance Updates 41, 1-25, 2018
4742018
Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance
S Narayanan, CY Cai, YG Assaraf, HQ Guo, Q Cui, L Wei, JJ Huang, ...
Drug Resistance Updates 48, 100663, 2020
2172020
Multidrug resistance proteins (MRPs): Structure, function and the overcoming of cancer multidrug resistance
JQ Wang, Y Yang, CY Cai, QX Teng, Q Cui, J Lin, YG Assaraf, ZS Chen
Drug Resistance Updates 54, 100743, 2021
1312021
Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters
YF Fan, W Zhang, L Zeng, ZN Lei, CY Cai, P Gupta, DH Yang, Q Cui, ...
Cancer letters 421, 186-198, 2018
1082018
Targeting cancer cell mitochondria as a therapeutic approach: recent updates
Q Cui, S Wen, P Huang
Future Medicinal Chemistry 9 (9), 929-949, 2017
752017
The targeting of non‑coding RNAs by curcumin: Facts and hopes for cancer therapy
Y Liu, H Sun, B Makabel, Q Cui, J Li, C Su, CR Ashby Jr, Z Chen, J Zhang
Oncology reports 42 (1), 20-34, 2019
582019
N‐Benzyldithiocarbamate Salts as Sulfur Sources to Access Tricyclic Thioheterocycles Mediated by Copper Species
B Luo, Q Cui, H Luo, Y Hu, P Huang, S Wen
Advanced Synthesis & Catalysis 358 (17), 2733-2738, 2016
492016
Venetoclax, a BCL-2 inhibitor, enhances the efficacy of chemotherapeutic agents in wild-type ABCG2-overexpression-mediated MDR cancer cells
JQ Wang, JY Li, QX Teng, ZN Lei, N Ji, Q Cui, L Zeng, Y Pan, DH Yang, ...
Cancers 12 (2), 466, 2020
442020
Repositioning lidocaine as an anticancer drug: the role beyond anesthesia
D Zhou, L Wang, Q Cui, R Iftikhar, Y Xia, P Xu
Frontiers in Cell and Developmental Biology 8, 565, 2020
382020
Erdafitinib antagonizes ABCB1-mediated multidrug resistance in cancer cells
W Feng, M Zhang, ZX Wu, JQ Wang, XD Dong, Y Yang, QX Teng, ...
Frontiers in oncology 10, 955, 2020
352020
Gaseous signaling molecules and their application in resistant cancer treatment: from invisible to visible
Q Cui, Y Yang, N Ji, JQ Wang, L Ren, DH Yang, ZS Chen
Future Medicinal Chemistry 11 (4), 323-336, 2019
342019
Midostaurin Reverses ABCB1-Mediated Multidrug Resistance, an in vitro Study
N Ji, Y Yang, CY Cai, JQ Wang, ZN Lei, ZX Wu, Q Cui, DH Yang, ZS Chen, ...
Frontiers in oncology 9, 514, 2019
322019
A novel danshensu derivative prevents cardiac dysfunction and improves the chemotherapeutic efficacy of doxorubicin in breast cancer cells
L Wang, X Zhang, JYW Chan, L Shan, G Cui, Q Cui, Y Wang, J Li, H Chen, ...
Journal of Cellular Biochemistry 117 (1), 94-105, 2016
322016
Design, synthesis, and preliminary cardioprotective effect evaluation of danshensu derivatives
Q Cui, Y Chen, M Zhang, L Shan, Y Sun, P Yu, G Zhang, D Wang, Z Zhao, ...
Chemical Biology & Drug Design 84 (3), 282-291, 2014
292014
Glesatinib, a c-MET/SMO dual inhibitor, antagonizes P-glycoprotein mediated multidrug resistance in cancer cells
Q Cui, CY Cai, HL Gao, L Ren, N Ji, P Gupta, S Shukla, SV Ambudkar, ...
Frontiers in Oncology 9, 313, 2019
272019
Modulating the function of ABCB1: in vitro and in vivo characterization of sitravatinib, a tyrosine kinase inhibitor
Y Yang, N Ji, CY Cai, JQ Wang, ZN Lei, QX Teng, ZX Wu, Q Cui, Y Pan, ...
Cancer Communications 40 (7), 285-300, 2020
262020
Chk1 inhibitor MK-8776 restores the sensitivity of chemotherapeutics in P-glycoprotein overexpressing cancer cells
Q Cui, CY Cai, JQ Wang, S Zhang, P Gupta, N Ji, Y Yang, X Dong, ...
International Journal of Molecular Sciences 20 (17), 4095, 2019
222019
Reversal of cancer multidrug resistance (MDR) mediated by ATP-binding cassette transporter G2 (ABCG2) by AZ-628, a RAF kinase inhibitor
JQ Wang, QX Teng, ZN Lei, N Ji, Q Cui, H Fu, L Lin, DH Yang, YF Fan, ...
Frontiers in Cell and Developmental Biology 8, 601400, 2020
212020
Reversal effect of ALK inhibitor NVP-TAE684 on ABCG2-overexpressing cancer cells
J Wang, JQ Wang, CY Cai, Q Cui, Y Yang, ZX Wu, X Dong, L Zeng, ...
Frontiers in oncology 10, 228, 2020
202020
Special Issue: Natural Products: Anticancer and Beyond
Q Cui, DH Yang, ZS Chen
Molecules 23 (6), 1246-1249, 2018
192018
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20